TROV TrovaGene Inc.

2.09
+0.46  (+28%)
Previous Close 1.63
Open 1.82
Price To Book 1.29
Market Cap 11,381,647
Shares 5,445,764
Volume 573,661
Short Ratio
Av. Daily Volume 105,252

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 presentation at ESMO September 27, 2019.
Onvansertib (PCM-075)
Acute Myeloid Leukemia (AML)
Phase 2 new data to be presented at Asia-Pacific Prostate Cancer Conference. August 24, 2019 1:00 pm (AEDT). Presentation also at ESMO September 27, 2019.
Onvansertib (PCM-075) and Zytiga
Prostate cancer
Phase 1b/2 trial initiation announced July 9, 2019.
Onvansertib, Folfiri and Avastin (bevacizumab)
KRAS-Mutated Colorectal Cancer

Latest News

  1. The Week Ahead In Biotech: FDA Goes Into Overdrive In A Quiet Week
  2. Trovagene to Present New Data from Onvansertib Phase 2 Study in Metastatic Castration-Resistant Prostate Cancer at Asia-Pacific Prostate Cancer Conference
  3. Trovagene Announces Second Quarter 2019 Results and Highlights
  4. ESMO Accepts Trovagene AML Clinical Trial Abstract for Oral Presentation
  5. Trovagene Commences Non-Deal Investor Roadshow
  6. Trovagene Announces Initiation of Enrollment for Phase 1b/2 Clinical Trial in KRAS-Mutated Colorectal Cancer at Leading Comprehensive Cancer Centers
  7. Trovagene to Host Business Update Conference Call on June 7, 2019
  8. Trovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD™ in Models of Colorectal Cancer
  9. Could TrovaGene, Inc.'s (NASDAQ:TROV) Investor Composition Influence The Stock Price?
  10. Trovagene Announces Equity Investment of $1.5 Million at Premium to Market Price from Institutional Investor, Lincoln Park Capital
  11. Trovagene: 1Q Earnings Snapshot
  12. Trovagene Announces First Quarter 2019 Results and Highlights
  13. Trovagene Announces Data Demonstrating Significant Synergy of Onvansertib in Combination with Venetoclax in Cell Model of Venetoclax-Resistant AML
  14. Trovagene Announces Update to Phase 1b/2 AML Trial Data Presented at AACR - Additional Patients Achieve Complete Response at Two Highest Dose Levels of Onvansertib
  15. Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital
  16. Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy
  17. Phase 1b/2 Dose Escalation Trial of Onvansertib in Relapsed/Refractory AML Demonstrates Safety, Tolerability and Relative Durability with Complete Responses at Highest Dose Levels
  18. Trovagene Receives Approximately $3.0 Million From Exercise of Warrants
  19. A Near Term FDA Clearance That Could Be The Beginning Of The Brain-Computer Revolution?
  20. Trovagene Regains Compliance with Nasdaq Listing Requirements